Neuren Pharmaceuticals: From New Zealand roots to ASX stardom

Neuren Pharmaceuticals: From New Zealand roots to ASX stardom
Neuren's Melbourne-based CEO Jon Pilcher credits the pharmaceutical firm's breakthrough medications to NZ research. (Image: Neuren Pharmaceuticals)
Rebecca Stevenson
It was the best-performing stock on the ASX in 2023, has a market cap of about $2.2 billion, doesn’t have an office, and was founded in New Zealand. Neuren Pharmaceutical’s medication trofinetide became the first US Food and Drug Administration (FDA) approved treatment for the disabling neurological disorder Rett syndrome in March 2023. Rett syndrome is rare, “profoundly debilitating”, and mostly affects female children. It leads to developmental delays and sometimes regressions as the child ages. Neuren s...

More Markets

NZ sharemarket flat amid global fears of Iran strike
Markets Market Close

NZ sharemarket flat amid global fears of Iran strike

NZ investors are looking with concern at rumblings in the Middle East.

Gas prices increase by up to 20%
Markets

Gas prices increase by up to 20%

Prices are up as some retailers decline new gas connections.

US consumers ignore tariffs on King Salmon
Primary Sector

US consumers ignore tariffs on King Salmon

Growth hopes are pinned on its new Cook Strait 'open ocean' farm.

Market lifts as Fletcher Building shares rally on buyer inquiries
Markets

Market lifts as Fletcher Building shares rally on buyer inquiries

Fletcher says it's had inquiries from parties interested in buying its businesses.

Tom Raynel 11 Jun 2025